These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 32772956

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I.
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA, Loft H, Olsen CK.
    J Affect Disord; 2019 May 01; 250():35-42. PubMed ID: 30826492
    [Abstract] [Full Text] [Related]

  • 5. The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder.
    Cao B, Park C, Subramaniapillai M, Lee Y, Iacobucci M, Mansur RB, Zuckerman H, Phan L, McIntyre RS.
    Front Psychiatry; 2019 May 01; 10():17. PubMed ID: 30766492
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study.
    Di Nicola M, Adair M, Rieckmann A, Christensen M C.
    J Psychopharmacol; 2024 Jul 01; 38(7):615-623. PubMed ID: 39077889
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of vortioxetine in patients with major depressive disorder and early-stage dementia: The MEMORY study.
    Christensen MC, Schmidt SN, Grande I.
    J Affect Disord; 2023 Oct 01; 338():423-431. PubMed ID: 37315590
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of vortioxetine in patients with major depressive disorder and co-morbid generalized anxiety disorder in routine clinical practice: A subgroup analysis of the RELIEVE study.
    Almeida SS, Christensen MC, Simonsen K, Adair M.
    J Psychopharmacol; 2023 Mar 01; 37(3):279-288. PubMed ID: 36377523
    [Abstract] [Full Text] [Related]

  • 9. Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.
    Di Nicola M, Pepe M, Montanari S, Spera MC, Panaccione I, Simonetti A, Sani G.
    Eur Neuropsychopharmacol; 2023 May 01; 70():21-28. PubMed ID: 36808043
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study.
    Christensen MC, Schmidt S, Grande I.
    J Psychopharmacol; 2022 May 01; 36(5):566-577. PubMed ID: 35499104
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.
    Cumbo E, Adair M, Åstrom DO, Christensen MC.
    Front Aging Neurosci; 2022 May 01; 14():1037816. PubMed ID: 36698860
    [Abstract] [Full Text] [Related]

  • 16. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT, Sluth LB, Olsen CK.
    J Affect Disord; 2018 Mar 15; 229():421-428. PubMed ID: 29331703
    [Abstract] [Full Text] [Related]

  • 17. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C, Sampson E, Mills NT, Baune BT.
    Trials; 2018 Aug 20; 19(1):447. PubMed ID: 30126458
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.